Remedent Statistics
Total Valuation
Remedent has a market cap or net worth of 192,730.
| Market Cap | 192,730 |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Friday, September 19, 2025.
| Earnings Date | Sep 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Remedent has 19.27 million shares outstanding.
| Current Share Class | 19.27M |
| Shares Outstanding | 19.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.85 |
| PB Ratio | 0.06 |
| P/TBV Ratio | 0.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63
| Current Ratio | 1.63 |
| Quick Ratio | 1.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -158.04 |
Financial Efficiency
Return on equity (ROE) is -9.96% and return on invested capital (ROIC) is -5.66%.
| Return on Equity (ROE) | -9.96% |
| Return on Assets (ROA) | -3.80% |
| Return on Invested Capital (ROIC) | -5.66% |
| Return on Capital Employed (ROCE) | -9.53% |
| Revenue Per Employee | 16,700 |
| Profits Per Employee | -110,145 |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.33 |
Taxes
In the past 12 months, Remedent has paid 483 in taxes.
| Income Tax | 483 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.33% in the last 52 weeks. The beta is -0.20, so Remedent's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | -83.33% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 20.06 |
| Average Volume (20 Days) | 56,112 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, Remedent had revenue of 50,100 and -330,436 in losses.
| Revenue | 50,100 |
| Gross Profit | 19,984 |
| Operating Income | -300,586 |
| Pretax Income | -329,952 |
| Net Income | -330,436 |
| EBITDA | -277,386 |
| EBIT | -300,586 |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 30,085 in cash and n/a in debt, giving a net cash position of 30,085 or 0.00 per share.
| Cash & Cash Equivalents | 30,085 |
| Total Debt | n/a |
| Net Cash | 30,085 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 3.15M |
| Book Value Per Share | n/a |
| Working Capital | 1.06M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 39.89% |
| Operating Margin | -599.97% |
| Pretax Margin | -658.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Remedent does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -171.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Remedent has an Altman Z-Score of 1.53 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.53 |
| Piotroski F-Score | 1 |